Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

NCT04643067 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

SLE; Drug

Interventions

DRUG: KPG-818 low dose
DRUG: KPG-818 mid dose
DRUG: KPG-818 high dose
DRUG: Placebo

Sponsor

Kangpu Biopharmaceuticals, Ltd.